Company Profile

Constellation Pharmaceuticals, Inc. discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The Company is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.

Employees

154

Sector

Biotechnology & Medical Research

More about the company

07/22/07	MorphoSys Out Licenses Pre-Clinical Oncology Program	CI
17/21/17	MorphoSys : Royalty Pharma Takes Equity Position in MorphoSys for $100 Million	MT
15/21/15	Constellation Announces Management Changes	CI
15/21/15	Constellation Pharmaceuticals, Inc. Announces Resignation of Jigar Raythatha as Chief Executive Officer	CI
15/21/15	Constellation Pharmaceuticals, Inc. Announces Resignation of Emma Reeve as Chief Financial Officer	CI
15/21/15	DJ Industrial : Wall Street Futures Mostly Lower, Jobless Claims Drop Less Than Expected; Powell Speech Eyed	MT
15/21/15	MorphoSys : Finalizes $1.7 Billion Acquisition of Constellation Pharmaceuticals	MT
15/21/15	MorphoSys : Completes Tender Offer for Constellation Pharmaceuticals	MT
15/21/15	Constellation Pharmaceuticals, Inc.(NasdaqGM:CNST) dropped from NASDAQ Composite Index	CI
15/21/15	Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P TMI Index	CI
15/21/15	Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Biotechnology Select Industry Index	CI
15/21/15	Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Global BMI Index	CI
15/21/15	MorphoSys AG completed the acquisition of Constellation Pharmaceuticals, Inc..	CI

17/21/17	CONSTELLATION PHARMACEUTICALS : RBC Capital Downgrades Constellation Pharmaceuticals to Sector Perform From Outperform, Price Target Cut to $34 From $50	MT
04/21/04	CONSTELLATION PHARMACEUTICALS : Jefferies Downgrades Constellation Pharmaceuticals to Hold From Buy, Adjusts Price Target to $34 From $53	MT
03/21/03	CONSTELLATION PHARMACEUTICALS : Truist Securities Downgrades Constellation Pharmaceuticals to Hold From Buy, Adjusts PT to $34 From $50	MT
03/21/03	CONSTELLATION PHARMACEUTICALS : BMO Capital Downgrades Constellation Pharmaceuticals to Market Perform from Outperform, Adjusts Price Target to $34 from $48	MT
03/21/03	CONSTELLATION PHARMACEUTICALS : JPMorgan Downgrades Constellation Pharmaceuticals to Neutral from Overweight, Adjusts Price Target to $34 from $38	MT

19/21/19	Royalty Pharma : MorphoSys Concludes a US$ 100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma	AQ
17/21/17	MorphoSys AG :	AQ
15/21/15	Constellation Pharmaceuticals : Completion of Acquisition or Disposition of Assets (Form 8-K)	PU
15/21/15	CONSTELLATION PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ
14/21/14	Constellation Pharmaceuticals : Provides an Update from the Ongoing MANIFEST Study of Pelabresib	AQ

29/21/29	Morphosys macht mehr Umsatz - Operativer Verlust höher
29/21/29	Morphosys verbucht in 2Q dank Finanzerträgen Gewinn
27/21/27	AKTIE IM FOKUS 2: MorphoSys setzen Talfahrt fort - Commerzbank streicht 'Buy'
26/21/26	MÄRKTE EUROPA/Etwas leichter - Bitcoin mit Rally
26/21/26	XETRA-SCHLUSS/Leichte Abgaben zu Wochenbeginn - Morphosys brechen ein

Manager	Title	Age	Since
John McKenna PSD	President	-	-
Kia Khalaghpour IRC	Investor Relations Contact	-	-
Irina Apostolou PRN	Corporate Officer/Principal	-	01/08/2016

Constellation Pharmaceuticals, Inc. Share Price

Stocks

CNST

US2103731061

Biotechnology & Medical Research

Latest news : Constellation Pharmaceuticals, Inc.

Analysts' recommendations: Constellation Pharmaceuticals, Inc.

Press Releases: Constellation Pharmaceuticals, Inc.

News in other languages: Constellation Pharmaceuticals, Inc.

Quotes and Performance

Managers and Directors: Constellation Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Director	Title	Age	Since
Kathleen Warnecke BRD	Director/Board Member	-	15/07/2021
John McKenna BRD	Director/Board Member	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/07/21	Scott Braunstein	Issuer sale	Director	52,684	0.1098%
15/07/21	Patric Trojer	Issuer sale	Chief Technology Officer	3,65,758	0.7625%
15/07/21	Richard Levy	Issuer sale	Director	39,513	0.0824%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CONSTELLATION PHARMACEUTICALS, INC.	+0.06%	+0.12%	-	-	162.47Cr
WUXI APPTEC CO., LTD.	+1.23%	-3.08%	+53.96%	+87.98%	5.53TCr
ARGENX SE	+5.09%	+6.18%	+63.69%	+62.06%	5.42TCr
INSMED INCORPORATED	+0.72%	-0.05%	+3.84%	+424.98%	2.31TCr
BIONTECH SE	+0.25%	+0.55%	-19.67%	-13.99%	2.32TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.03%	-0.76%	+40.14%	-3.59%	2.03TCr
GENMAB A/S	-0.37%	+0.42%	+37.47%	-31.61%	1.79TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.87%	-2.80%	+37.96%	+600.00%	1.58TCr
PHARMAESSENTIA CORPORATION	-2.54%	-12.88%	+168.62%	+289.45%	1.5TCr
EXELIXIS, INC.	+1.22%	-0.05%	+22.58%	+179.79%	1.38TCr
Average	+0.76%	-0.37%	+45.40%	+177.23%	2.65TCr
Weighted average by Cap.	+1.55%	+1.19%	+46.06%	+139.85%